[The pharmacokinetic and biopharmaceutical evaluation of the new tranquilizer gidazepam].
The pharmacokinetics of the new tranquilizer gidazepam and its desalkyl metabolite was studied in rats. Some biopharmaceutical characteristics of the agents under study were defined. Gidazepam was found to have much advantage over the principal active ingredient (desalkylgidazepam) in its higher bioavailability. The methodological approaches developed by the authors to evaluate the efficacy of gidazepam may be applied in designing novel drugs.
Kolyvanov
G B
GB
Kruchenkov
A A
AA
Litvin
A A
AA
Zherdev
V P
VP
Otabekova
S G
SG
D000818:Animals; D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000737:chemistry / Q000493:pharmacokinetics*; D001702:Biopharmaceutics; D001711:Biotransformation; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D011355:Prodrugs / Q000737:chemistry / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D011355:Prodrugs; D001569:Benzodiazepines; C077010:gidazepam
Farmakokineticheskaia i biofarmatsevticheskaia otsenka novogo trankvilizatora gidazepama.